EOLO PHARMA announced that it has received approval to initiate a Phase 1 clinical trial for MVD1, the company’s investigational small molecule designed to reduce body weight and glucose levels in blood.
Carlos Escande, PhD., chief scientific officer, EOLO PHARMA, said: “EOLO’s leading molecule MVD1 has shown very promising results in the prevention and treatment of obesity, type II diabetes and fatty-liver disease in preclinical models. MVD1 works through a novel metabolic pathway that promotes energy expenditure promising to have a high functionality in humans. Activation of resting energy expenditure in white adipose tissue, a process known as “beigeing” is currently envisioned as a valid therapeutic strategy for obesity and metabolic syndrome.
EOLO’s MVD1 is the first-in-class small molecule targeting this novel pathway that is now reaching clinical testing. Assessing MVD1 safety and efficacy in humans is a landmark for our company that will pave the road for novel treatments for these devastating diseases”.
An application for approval of the clinical trial was submitted for review and approval to a national, unaffiliated, non-institutional Human Research Ethics Committee who provide a streamlined and ethical review of clinical trials across Australia., where EOLO PHARMA is starting a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MVD1 in up to 24 healthy volunteers and in up to 24 overweight or obese patients with alterations of blood glucose.
About EOLO PHARMA
EOLO PHARMA develops small molecules aimed to treat chronic metabolic diseases, such as obesity, type II diabetes and cardiovascular diseases. However, its portfolio of molecules goes beyond that. EOLO’s technology has proved to be effective for several diseases that involve low-grade chronic inflammation. As such, EOLO’s team of world class scientists, in cooperation with the Institut Pasteur de Montevideo and Universidad de La República, is currently also developing small molecules that are effective in preclinical models of neurodegenerative and autoimmune diseases. As a result of its innovative and disruptive approach to drug design, EOLO has a portfolio of protected small molecules with the potential of targeting metabolic, aging and immune diseases.